Clinical Trials

Numerous clinical trials, ranging from Phase 1 through Phase 4 alongside non-interventional studies, evaluate the therapeutic and physiological effects of NAD+ and its precursors in healthy cohorts and conditions such as Parkinson's disease, Leber hereditary optic neuropathy, Smooth Muscle Dysfunction Syndrome, acute organ injuries, sarcopenia, and Long COVID-19. Sponsored by academic, government, and industry leaders—including Charité University Berlin, the VA Office of Research and Development, and ChromaDex Inc.—these trials exhibit recruitment statuses ranging from completed and actively recruiting to enrolling by invitation.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06853743 RECRUITING
Huntington Disease
Oslo University Hospital
 2025-03-18 PHASE2
NCT06162013 RECRUITING
Progressive Supranuclear Palsy; Multiple System Atrophy; Corticobasal Syndrome
Haukeland University Hospital
 2024-03-05 PHASE2
NCT07739290 NOT_YET_RECRUITING
Acute Kidney Injury
Beth Israel Deaconess Medical Center
 2026-09-01
NCT06032923 RECRUITING
Systemic Lupus Erythematosus (Sle)
National Heart, Lung, and Blood Institute (NHLBI)
 2024-03-13 PHASE1; PHASE2
NCT06208527 RECRUITING
Frailty; Frail Elderly Syndrome; Frailty Syndrome; Aging
Haukeland University Hospital
 2025-01 PHASE2
NCT07751341 NOT_YET_RECRUITING
Advanced Esophageal Squamous Cell Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
 2026-08 PHASE2
NCT07649161 RECRUITING
Healthy Adult
Massachusetts General Hospital
 2026-06
NCT06627868 RECRUITING
Obesity, Abdominal
University of Turku
 2024-11-20
NCT07416786 NOT_YET_RECRUITING
Healthy Adults
University of Pennsylvania
 2026-07-01
NCT07703137 ENROLLING_BY_INVITATION
Parkinson's Disease
University of Oklahoma
 2026-08-10
NCT06966583 NOT_YET_RECRUITING
Solid Tumor; Non Small Cell Lung Cancer
Sichuan University
 2025-05-01 PHASE1
NCT05483465 RECRUITING
Aging
University of Oklahoma
 2023-05-03 PHASE4
NCT07563322 RECRUITING
Pulmonary Hypertension
Vanderbilt University Medical Center
 2026-04-09
NCT07692633 NOT_YET_RECRUITING
NAD+ Bioavailability; NAD+ Safety; NAD+ Efficacy
Reus Research
 2026-08
NCT06882096 RECRUITING
Healthy Adults
Metro International Biotech, LLC
 2025-04-28 PHASE1
NCT05759468 RECRUITING
Type2diabetes; Diabetic Kidney Disease
Brigham and Women's Hospital
 2023-04-13 PHASE2
NCT06866236 NOT_YET_RECRUITING
Chronic Kidney Diseases; Acute Kidney Injury; Kidney Failure
Ebima Clifford Okundaye
 2025-10 PHASE2; PHASE3
NCT05194397 RECRUITING
Lymphoblastic Leukemia; Cancer Survivors; Aplastic Anemia; Myelodysplastic Syndromes; Myeloid Leukemia
Children's Hospital of Philadelphia
 2023-02-23 PHASE2
NCT06971224 RECRUITING
Sleep
Haukeland University Hospital
 2025-10-13 PHASE2
NCT07428889 COMPLETED
Healthy Adult
Shaklee Corporation
 2026-02-17
NCT07475546 ACTIVE_NOT_RECRUITING
Healthspan Improvement; Aging; Longevity
AgelessRx
 2025-07-23 PHASE3
NCT06579209 COMPLETED
Cognitive Change; Inflammation; Neurodegenerative Diseases
University of Rhode Island
 2024-12-01
NCT06991712 RECRUITING
Glaucoma
Christopher Kai Shun Leung
 2025-05-19 PHASE2
NCT05040321 COMPLETED
Alzheimer's Disease (Incl Subtypes); Dementia
Brigham and Women's Hospital
 2021-12-01 PHASE1; PHASE2
NCT06425042 RECRUITING
Healthy Aging; Lifestyle-related Condition; Metabolic Diseases
Finis Terrae University
 2024-03-01
NCT07132801 NOT_YET_RECRUITING
NAD; NAD+ Levels in the Blood
Qualia Life Sciences
 2025-10-13
NCT07203131 RECRUITING
Acute Renal Insufficiency; NAD
GCS Ramsay Santé pour l'Enseignement et la Recherche
 2025-03-17
NCT04750616 RECRUITING
Ischemia Reperfusion Injury; Myocardial Injury; Acute Kidney Injury
Kaiser Permanente
 2021-09-13 PHASE2
NCT06919328 RECRUITING
Healthy Aging
Nutraceuticals Research Institute
 2024-10-31
NCT04192136 COMPLETED
Friedreich Ataxia 1
Children's Hospital of Philadelphia
 2020-09-03
NCT04870866 ACTIVE_NOT_RECRUITING
Ataxia Telangiectasia
University Hospital, Akershus
 2019-06-05 PHASE2
NCT06948292 COMPLETED
Chronic Kidney Disease Stages 3-5; Diabetic Kidney Disease; Hypertensive Kidney Disease
Ebima Clifford Okundaye
 2023-03-01 PHASE2
NCT06505967 UNKNOWN
NAD+ Levels in the Blood
Qualia Life Sciences
 2024-06-10
NCT06534944 COMPLETED
Peripheral Artery Disease
University of Oklahoma
 2023-02-27 PHASE1; PHASE2
NCT05938556 COMPLETED
Burnout, Professional
Emory University
 2023-07-14
NCT06036355 UNKNOWN
Postoperative Prevention of Tumor
Shanghai Cell Therapy Group Co.,Ltd
 2023-09-30 EARLY_PHASE1
NCT06812416 COMPLETED
Intracellular NAD+ Levels
Qualia Life Sciences
 2023-10-24
NCT06382688 UNKNOWN
Healthy Aging
Nutraceuticals Research Institute
 2023-11-13
NCT05698771 COMPLETED
Healthy
Haukeland University Hospital
 2022-09-17 PHASE1
NCT06280482 Recruiting
Smooth Muscle Dysfunction Syndrome (SMDS)
The University of Texas Health Science Center Houston
 2024-03-06 Phase 1
NCT05984550 UNKNOWN
Enhance Immune Function
Shanghai Cell Therapy Group Co.,Ltd
 2023-08 EARLY_PHASE1
NCT03482167 COMPLETED
Mild Cognitive Impairment
University of Delaware
 2019-03-20 PHASE1; PHASE2
NCT06005350 Recruiting
NAD
Charite University Berlin Germany|ChromaDex Inc.
 2023-11-01 Not Applicable
NCT05405309 TERMINATED
Chronic Lymphocytic Leukemia
University of Utah
 2022-09-23 PHASE1; PHASE2
NCT04809974 COMPLETED
Covid19; Sequelae of; Infection; Cognitive Symptom
Massachusetts General Hospital
 2021-08-28 PHASE4
NCT06036355 Not yet recruiting
Postoperative Prevention of Tumor
Shanghai Cell Therapy Group Co.Ltd
 2023-09-30 Early Phase 1
NCT04691986 Recruiting
Sarcopenia|Nicotinamide Adenine Dinucleotide Concentration|Muscle Quality and NAD+ Content
VA Office of Research and Development|University at Buffalo
 2023-09-01 Not Applicable
NCT05038488 COMPLETED
Covid19; Stage 1 Acute Kidney Injury
Metro International Biotech, LLC
 2021-10-26 PHASE2
NCT06143423 TERMINATED
Diabetes Mellitus, Type 2
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
 2023-05-24 PHASE1
NCT04604704 COMPLETED
Covid19; Long COVID-19; Post-COVID-19 Syndrome
AgelessRx
 2021-01-28 PHASE2
NCT05517122 COMPLETED
Healthy
Société des Produits Nestlé (SPN)
 2022-07-12
NCT03151707 TERMINATED
Healthy
Mclean Hospital
 2017-10-01 PHASE4
NCT05298410 COMPLETED
Hypertension
Limitless Research Inc.
 2022-03-17 PHASE2
NCT02721537 COMPLETED
Concussion, Mild
Mayo Clinic
 2016-09
NCT04905446 COMPLETED
Skeletal Muscle
AdventHealth Translational Research Institute
 2021-09-10
NCT07336836 COMPLETED
Health Adult Subjects; Healthy Participants
BioNADrx Holdings, Inc. Bryleos
 2022-02-23 EARLY_PHASE1
NCT04817111 COMPLETED
Friedreich Ataxia
Metro International Biotech, LLC
 2021-05-17 PHASE2
NCT03723291 COMPLETED
Head and Neck Fibrosis
University College, London
 2019-09-01 PHASE1
NCT04538521 COMPLETED
Mitochondrial Myopathies
University of Helsinki
 2019-02-11
NCT02064569 COMPLETED
Leber Hereditary Optic Neuropathy
GenSight Biologics
 2014-02-13 PHASE1; PHASE2
NCT03186027 COMPLETED
Chronic Fatigue Syndrome
Hospital Universitari Vall d'Hebron Research Institute
 2017-06-28
NCT03310034 TERMINATED
Aging; Mitochondrial Function
Maastricht University
 2017-11-01
NCT03816020 COMPLETED
Parkinson Disease; Neurodegenerative Diseases
Haukeland University Hospital
 2019-03-09
NCT05113914 COMPLETED
Healthy
Poznan University of Physical Education
 2011-01-01
NCT02942888 COMPLETED
Mild Cognitive Impairment; NAD
The University of Texas Health Science Center at San Antonio
 2017-11-30
NCT03967678 COMPLETED
CVD; Cholesterol; Metabolic Disorder; Inflammation
University of Ulster
 2018-11-07
NCT02950441 UNKNOWN
Aging
University of Birmingham
 2016-06 PHASE2
NCT02389660 COMPLETED
Depression
University of Social Sciences and Humanities, Warsaw
 2015-06
NCT03707652 COMPLETED
Increase in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)
Supplement Formulators, Inc.
 2018-03-12
NCT03973203 COMPLETED
Mitochondrial Myopathies
University of Helsinki
 2014-06-01
NCT02010151 COMPLETED
Out of Hospital Cardiac Arrest
Seoul National University Hospital
 2015-03
NCT01937767 COMPLETED
General Anesthesia
Paion UK Ltd.
 2013-08 PHASE2
NCT01566799 UNKNOWN
Locally Advanced Malignant Neoplasm
Instituto Nacional de Cancerologia de Mexico
 2012-04 PHASE2
NCT02063126 COMPLETED
Chronic Fatigue Syndrome
Hospital Universitari Vall d'Hebron Research Institute
 2013-01 PHASE2; PHASE3
NCT01269801 COMPLETED
Wrinkles
AboutSkin Dermatology and DermSurgery, PC
 2011-01 PHASE4
NCT00454948 COMPLETED
Obesity
Stanford University
 2007-03
NCT00465907 TERMINATED
Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2003-05 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-03-19)

Check the NAD+ (β-DPN) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an essential metabolic coenzyme, NAD+ binds key oxidoreductases and enzymatic acceptors to participate in mitochondrial electron transport and cellular oxidation-reduction reactions, driving ATP synthesis and supporting cellular bioenergetics. By serving as a critical substrate for sirtuins and PARP enzymes, NAD+ replenishment restores mitochondrial function and maintains redox homeostasis, offering therapeutic potential for conditions characterized by cellular energy depletion and tissue dysfunction, such as acute kidney injury, sarcopenia, and neurodegenerative diseases like Parkinson's disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.